Areas of Expertise
- Pharmaceutical Compliance MonitorApril 19, 2013
- Pharmaceutical Compliance MonitorMarch 18, 2013
Seminars & Speaking Engagements
- February 28, 2013
News & Commentary
- Press releaseFebruary 11, 2013
Edward Buthusiem advises clients on a variety of business, regulatory, operational, intellectual property, litigation, transactional, and compliance matters, with particular emphasis in legal operations, commercial and strategic transactions, technology licensing arrangements, business formation and planning, securities, mergers and acquisitions, compliance, and corporate governance. He previously served as the general counsel of two major divisions of two multinational companies and as an attorney in the business, securities, and international law practice groups at two global law firms.
In November 2010, Mr. Buthusiem joined Danaher Corporation’s Kavo Kerr Group as general counsel of its $2.3-billion dental medical device business. He built processes for and managed all aspects of legal support, including compliance, intellectual property, litigation, mergers and acquisitions, commercial transactions, and counseling on a variety of laws, including FDA regulatory, antitrust, labor and employment, OFAC, trade, global anti-bribery/anti-corruption, and fraud and abuse. Mr. Buthusiem also built, globalized, and managed the Global Environmental Health and Safety and Global Trade Compliance departments. Each global function formed an integral part of the manufacturing and supply internal control and compliance structure, which supported a global manufacturing and supply organization, and the movement of goods and services in over 77 different countries.
Before joining Danaher, Mr. Buthusiem spent 20 years with GlaxoSmithKline in various senior positions in GSK’s global legal department. He led the strategic planning and financial management function of GSK’s legal department; and led GSK’s securities law practice area, which included responsibility for all U.S. and UK securities disclosures and regulatory filings. He formed and led the GSK crisis management team on pandemic vaccines, and he was legal counsel to the GSK Avandia crisis management team responsible for preparing for and delivering GSK’s Congressional testimony to the House Oversight Committee. Mr. Buthusiem also led GSK Legal’s cost-reduction and efficiency initiative, which resulted in substantial cost savings and operational improvements in the delivery of global legal services.
For the previous eight years, Mr. Buthusiem was general counsel to GSK’s Global Research and Development and Vaccines and Risk Management departments; he oversaw and coordinated global legal support for pharmaceuticals and vaccines research and development, including litigation management and strategy, regulatory and governmental affairs, clinical development, drug discovery, genomics and genetics research, and business development, including licensing and technology transactions and mergers and acquisitions. Prior to this role, he managed the Strategic and Scientific Transactions group, which had global responsibility for preparing, negotiating, and managing legal support in connection with strategic and science-based transactions for all sectors of the company.
- University of Pennsylvania
- Temple University
- Kavo Kerr Group (Danaher's medical device business)
2010 - 2012
Senior vice president and special counsel
2008 - 2010
Senior vice president of R&D Legal Operations and Biologicals
1999 - 2008
Vice president of Business and Corporate Development Legal Transactions
1994 - 1999
Legal transactional specialist
1990 - 1994